Quanterix Corporation · NASDAQ:QTRX
Quanterix — J.P. Morgan Healthcare Conference 2025
31 slides from Quanterix's conference presentation, Jan 15, 2025
Slide 1: J.P. Morgan Healthcare Conference 2025
„ J.P. Morgan Healthcare Conference 2025 Masoud Toloue, CEO January 15, 2025
Slide 2: Legal Information
Legal Information IMPORTANT ADDITIONAL INFORMATION In connection with the proposed acquisition of Akoya Biosciences, Inc. (“Akoya”) by Quanterix, Quanterix will file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (the “Registration Statement”), whic
Slide 3: Legal Information
Legal Information CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements included in this presentation that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provid
Slide 4: Create the tools enabling discovery and better health
OUR MISSION Create the tools enabling discovery and better health Unmatched >1000 Instruments 32 Technology installed Preliminary 2024 Revenue1 Cash burn1 2024 Non-GAAP Gross Cash Balance 1 Margin2 Guidance Early penetration in CLIA lab running multi-billion diagnostics validated neuro LDTs Biomarke
Slide 5: Traditional Protein assays
Analog Traditional Digital Protein assays Millions of molecules needed to reach detection limit SUBSTRATE 0 pM 10 pM 0 aM 3.5 aM 350 aM 3.5 fM 5
Slide 6: Simoa detects biomarkers unmeasurable by other technology
Simoa detects biomarkers unmeasurable by other technology Sensitivity level Low Late stage 15B molecules disease ELISA biomarkers Requires high molecule Addressable Laser Bead Assay concentration 15M molecules Chemiluminescence Proximity Extension Assay Electro-chemiluminescence 15K molecules Proxim
Slide 7: Catching disease early enables health-care
Catching disease early enables health-care… …versus today's sick-care management STAGE OF INTERVENTION HEALTHY LATE DISEASE Non-invasive Non-invasive Invasive Earliest stage detection Competitors Technologies 7
Slide 8: Strong Operational Execution
2 year CAGR 7 consecutive quarters of 14% of double-digit growth Resilience in From ~65% to ~80% customer stickiness Successful From 35% to 53%2 Strong execution of FIX Operational From $58M to $32M Ability to optimize Execution overall efficiency Building the From <5 to 20 new assays Executing a r
Slide 9: Strategic Priorities
Grow Menu Extend #1 position in Neuro Expand Strategic into adjacencies Immunology and Oncology Priorities Building on Top of Translate our Base into diagnostics Clinical applications and Alzheimer’s Disease testing 9
Slide 10: Our product development engine is in motion
Priority Our product development engine is in motion Menu 12 markers in Neurology incl. Lucent AD Complete (Multi-marker: p-Tau217, Aβ42, Aβ40, NfL, GFAP) Launched 5 new assays Launched 8 markers in One LDT Test 20 Immunology incl. 3 multi-markers in new assays inflammation Harmonized processes driv
Slide 11: Delivering the latest innovation to our customers
Priority Delivering the latest innovation to our customers Menu NfL Blood-based Plasma-based BD-Tau solution: Single and Multiplex Formats Simoa Neuro BD-Tau Assays BD- EVs Groundbreaking 4-plex assay N4PD: NfL, GFAP, UCHL-1, AD-specific BD-Tau Brain-specific Extracellular Vesicle (EV) profiling wit
Slide 12: New markets as neuroinflammation pathways accelerate
Priority New markers as neuroinflammation pathways accelerate Menu Precise detection of key Cytokine 4-Plex Panels Mood Disorder inflammatory and address translational research proinflammatory cytokines needs in inflammation & Immuno-oncology immunology Asthma IL-1𝐵𝐵 IL-6 Inflammation IL-1β IL-2…
Slide 13: Strategic Priorities
Grow Menu Expand Neuro menu Expand Strategic into adjacencies Immunology and Oncology Priorities Building on Top of Translate our Base into diagnostics Clinical applications and Alzheimer’s Disease testing 13
Slide 14: Increase addressable research from $1B to $5B
Priority Increase addressable research from $1B to $5B Adjacencies + Oncology Tissue to blood test continuum 5B * + Immunology Low to Mid-plex Segment 3B * Neurology Research Use Segment 1B* Historic focus * Management’s estimate; Excludes Dx and CDx 14
Slide 15: SIMOA In All Labs
Priority Adjacencies T O D AY SIMOA Accelerating our In All Labs expansion into not just speciality Immunology & Oncology Neuro Labs 15
Slide 16: SIMOA One
Priority Adjacencies SIMOA One Breaking past detection limits set by SIMOA N E W P L AT F O R M L A U N C H END OF 2025 16
Slide 17: Immunology: 10-plex capability and enhanced specificity
Priority Adjacencies Immunology Extends our Up to 01 #1 lead position 10x more sensitive in ultra-sensitivity compared to current SIMOA Enter a 02 10-plex capability $2B+ addressable while maintaining ultra-sensitivity mid-plex segment Optically encoded barcodes on Enhanced specificity proprietary 0
Slide 18: Accelerate entry into Oncology
Priority Adjacencies Oncology Protein based tests have become increasingly important in testing and monitoring, and multi-omics-based Accelerate entry approaches hasten need into Oncology Accelerating effort by measuring biomarkers as they first transition from tissue to blood 18
Slide 19: Quanterix and Akoya: Uniquely positioned to accelerate new tests
Priority Quanterix and Akoya: Uniquely positioned to accelerate new tests Adjacencies Oncology Ultra-sensitive Spatial detection and From identification of proteomic biomarkers Technology biomarker detection characterization of biomarkers to their detection Sample Blood Tissue From Tissue to Blood A
Slide 20: Oncology: Quanterix has already begun developing these tests
Priority Adjacencies Oncology Tissue leaks Biomarkers originating in biomarkers into blood SIMOA ultra-sensitivity Tissue identified by Spatial detecting those organization using Akoya in ultra-low quantities markers in Blood PDL-1 ORF1p IFN-γ sPD-L1 HEr2-Low PDL-1 EVs First Tissue / Blood Complemen
Slide 21: Accelerated Path to Scale and Profitability with Focus on Adjacencies
Priority Accelerated Path to Scale and Profitability with Focus on Adjacencies High Growth Markets Oncology 01 Growth Combined install base of 2,300 offers immediate cross-selling opportunities Combined revenue of ~$220M2 Scale Expected strong double-digit organic revenue growth by 2026 Significant
Slide 22: Strategic Priorities
Grow Menu Expand Neuro menu Expand Strategic into adjacencies Immunology and Oncology Priorities Building on Top of Translate our Base into diagnostics Clinical applications and Alzheimer’s Disease testing 22
Slide 23: Estimated $10 Billion AD testing segment
Priority Estimated $10 Billion AD AD Dx testing segment globally living with Alzheimer’s will play a large role enabling: By 2050 projected to Early detection Monitoring Differential diagnosis global societal cost of dementia in 2019 Source: 2023 Alzheimer’s Disease Facts and Figures from Alzh
Slide 24: Building the Global Infrastructure for Alzheimer's Disease Testing
Priority AD Dx BUILDING THE GLOBAL INFRASTRUCTURE FOR Alzheimer's Disease Testing I N T W O PAR T S … 24
Slide 25: Growing Network of Labs Serving Clinical Market in 2025
Priority AD Dx PAR T 1 : E N AB L E PAR T N E R S S O M E E X AM P L E S DEM O NST RAT I NG EARLY SUCCESS I N L AB ENABL EM ENT 12 PART NERS TO DAY Neurogen Our Partners Across the Globe Growing Network of Labs Serving Clinical 10+ partners in pipeline validating test Market in 2025 25
Slide 26: Best Multi-marker Test, Differentiated Reimbursement, High Capacity Infrastructure
Priority AD Dx PAR T 2 : O U R L AB Best Multi-marker Test Differentiated Reimbursement High Capacity Infrastructure 26
Slide 27: LucentAD Complete
Priority LucentAD Complete AD Dx A test for all patients, ALL +90% 01 not just late-stage AD 100% patients receive Sensitivity a result1 Lowest vs. >30% Intermediate +90% 02 Intermediate Zone 11% for a single marker Specificity 5 markers Algorithm to leverage 03 Future differential in 1 test additio
Slide 28: Value based - differentiated reimbursement
Priority Value based - differentiated reimbursement AD Dx Area of focus Multi Marker PLA code submitted (approval est. in Q1’25) Est. $700-800 Cross walked to several Est. H2’25 existing multi-marker tests Algorithm based risk score for test output Strong evidence of validity and utility ADLT Advanc
Slide 29: Building the global infrastructure for Alzheimer's Disease Testing
Priority Building the global infrastructure for Alzheimer's Disease Testing AD Dx 4 Prospective studies 0.75M Testing capacity 16 Diagnostics Team $20 Ongoing Trials BioHermes II Building Lab capacity 30+ team offering Commercial team Dedicated team of Million 100% enrollment Q4 2025 Davos Mt Sinai
Slide 30: Strategic Priorities
Grow Menu Extend #1 position in Neuro Expand Strategic into Adjacencies Immunology and Oncology Priorities Building on Top of Translate our Base into Diagnostics Clinical applications and Alzheimer’s Disease testing 30
Slide 31: Accelerating Growth, Extending Our Leadership Position
Accelerating Growth, Extending Our Leadership Position Unmatched Technology Most Sensitive Protein Measurements in Blood protected by a strong IP Delivering double-digit revenue growth In a constrained capital spending environment due to a differentiated business model Driving Operational Execution